Flanders Red Cross progress research into a nasal spray to prevent the transmission of the virus

During the Covid 19 pandemic, the Flemish Red Cross initiated research into a nasal spray to reduce virus transmission. Five years later, attempts at laboratory showed that the spray is highly effective and the way for human experiments and attempts to paving several viruses.

The spray is based on a more precise blood plasma of people who have recovered that contains viral -specific antibodies. These antibodies could help protect endangered people from infections.

Faster reaction to pandemics

While vaccines and antiviral medicines remain the key to controlling viral outbreaks, says Professor Hendrik Feys, director of scientific research at Flanders of the Red Cross, a nasal spray that comes from a convalescence plasma could enable a faster reaction to future pandemics. It would offer protection for endangered population groups and health workers at the forefront, especially in developing countries.

Earlier attempts have confirmed the effectiveness of the spray against coronaviruses. The next phase will test its effect on other viruses, including influenza and breathing syncytial virus (RSV), a common breathing virus, the nose, throat and lung. If the results are still positive, the studies of humans could begin by the end of the year, whereby a complete assessment is expected within three years.

Globally accessible

The technology could become globally accessible because plasma can be collected and processed locally, which enables quick deployment. Feys emphasizes that this approach could serve as an interim solution before vaccines become available, especially in regions with limited access to vaccines.

The prospects for the technology are promising. While the nature of future pandemics remains uncertain, this research is an important step towards faster and more efficient virus containment strategies.

^{#Flandersnewservice | © Imagebroker}

Related messages